Endomorphin-2 at High Doses Causes Pain Through Dynorphin Release — Turning Painkiller Into Pain Maker | Research

The takeaway

At high spinal doses, endomorphin-2 paradoxically produced pain (anti-analgesia) by triggering dynorphin release, which then activated NMDA receptors — revealing how excessive opioid signaling can flip from pain relief to pain generation.

Painkiller → pain maker
At high spinal doses, the opioid endomorphin-2 flipped from reducing pain to CAUSING it through dynorphin-NMDA signaling — the mechanism of opioid-induced hyperalgesia

What the researchers found

High-dose intrathecal endomorphin-2 produced anti-analgesia through spinal dynorphin release activating NMDA receptors, demonstrating a dose-dependent flip from opioid analgesia to opioid-induced pain generation.

Why it matters

Opioid-induced hyperalgesia (more pain from more opioids) is a major clinical problem. This study reveals the mechanism: excess opioid triggers dynorphin → NMDA activation → pain. Understanding this guides clinical opioid dosing.

How the study worked

Animal study. Intrathecal endomorphin-2 at escalating doses. At high doses (1.75-35 nmol), anti-analgesia measured. Anti-dynorphin antibodies and MK-801 (NMDA blocker) used to dissect the mechanism.

What this study cannot tell us

Mouse study with intrathecal injection. The dose range where the flip occurs may differ in humans.

How to read the evidence

Preliminary animal evidence with clear dose-dependent flip and mechanistic dissection through selective blocking.

When this study was published

Published in 2003. The dynorphin-NMDA mechanism of OIH has been confirmed and informs clinical ketamine co-therapy for opioid patients.

The bigger picture

The paradox of opioids causing pain at high doses has plagued clinical medicine. This dynorphin-NMDA mechanism explains the phenomenon and suggests combination therapy (opioid + NMDA blocker) could prevent it.

Questions still open

Could NMDA antagonists (ketamine) prevent opioid-induced hyperalgesia?
Is this dynorphin mechanism responsible for OIH in chronic pain patients?
Would lower opioid doses plus NMDA blockers achieve better pain relief?

Common questions

Can painkillers cause more pain?

Yes — this study proves it at the molecular level. At high doses, the opioid endomorphin-2 triggered dynorphin release which activated NMDA pain receptors, flipping from pain relief to pain generation.

What can be done about this?

NMDA blockers (like ketamine) can prevent the dynorphin-NMDA pain flip. This is already used clinically — low-dose ketamine alongside opioids prevents opioid-induced hyperalgesia.

Read the original research

Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.

The Journal of pharmacology and experimental therapeutics, 307(3), 1135-41

View on PubMed ↗

Citation

Wu, Hsiang-En; Sun, Han-Sen; Darpolar, Moses; Leitermann, Randy J; Kampine, John P; Tseng, Leon F. (2003). Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.. The Journal of pharmacology and experimental therapeutics, 307(3), 1135-41.